SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. During the same period last year, the firm posted ($1.34) EPS. On average, analysts expect SELLAS Life Sciences Group to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
SELLAS Life Sciences Group Trading Down 7.1 %
NASDAQ SLS traded down $0.12 on Friday, reaching $1.56. The company's stock had a trading volume of 1,847,845 shares, compared to its average volume of 1,401,895. The firm has a market cap of $147.49 million, a PE ratio of -2.26 and a beta of 2.34. The business has a 50-day moving average price of $1.26 and a 200 day moving average price of $1.19. SELLAS Life Sciences Group has a 52 week low of $0.77 and a 52 week high of $1.85.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
